Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1159/000508247 http://scihub22266oqcxt.onion/10.1159/000508247 32392562!7270061!32392562     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32392562&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+Arch+Allergy+Immunol 2020 ; 181 (6): 467-475 Nephropedia Template TP {{tp|p=32392562|t=2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 |pdf=|usr=}}{{32392562}} gab.com Text JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 JO: Int Arch Allergy Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32392562 #FOAvip After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world. Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed. In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease. Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1-7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries. However, more studies are needed to clarify the efficacy of these therapeutics. Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals. In addition to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19. Since the combination of MTX and baricitinib leads to outstanding clinical outcomes, the addition of baricitinib to MTX might be a potential strategy. Twit Text FOAVip JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 ????Int Arch Allergy Immunol http://www.kidney.de/pget.php?&tw=1&pmid=32392562 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32392562 #FOAvip English Wikipedia <ref>{{Cite pmid|32392562}}</ref> JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 #MMPMID32392562 Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D Int Arch Allergy Immunol 2020[]; 181 (6): 467-475 PMID32392562show ga After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world. Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed. In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease. Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1-7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries. However, more studies are needed to clarify the efficacy of these therapeutics. Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals. In addition to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19. Since the combination of MTX and baricitinib leads to outstanding clinical outcomes, the addition of baricitinib to MTX might be a potential strategy. |*Pandemics[MESH] |Angiotensin I/*therapeutic use[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Azetidines/*therapeutic use[MESH] |Betacoronavirus/drug effects/immunology/pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/epidemiology/immunology/virology[MESH] |Disease Progression[MESH] |Gene Expression Regulation[MESH] |Host-Pathogen Interactions/genetics/immunology[MESH] |Humans[MESH] |Janus Kinases/antagonists & inhibitors/*genetics/immunology[MESH] |Methotrexate/*therapeutic use[MESH] |Molecular Targeted Therapy/methods[MESH] |Peptide Fragments/*therapeutic use[MESH] |Peptidyl-Dipeptidase A/genetics/immunology[MESH] |Pneumonia, Viral/*drug therapy/epidemiology/immunology/virology[MESH] |Purines[MESH] |Pyrazoles[MESH] |Receptor, Angiotensin, Type 1/genetics/immunology[MESH] |SARS-CoV-2[MESH] |STAT Transcription Factors/antagonists & inhibitors/genetics/immunology[MESH] |Signal Transduction/genetics/immunology[MESH]JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 (epmc).pdf DeepDyve Pubget Overpricing